Biofield tries again with breast cancer detector
This article was originally published in Clinica
Biofield, a small US company which failed in an earlier attempt to commercialise a non-invasive breast cancer test, plans to relaunch the product in Europe later this year. The device, an electrical depolarisation test designed for use as an adjunct to mammography or physical examination in younger women with suspicious palpable breast lesions, has resumed CE-mark certification. The company has recertified to ISO 9001.
You may also be interested in...
Draft policy moots crowdfunding for high-cost rare diseases alongside financial support for those "amenable to one-time treatment" but falls way short of some patient groups' expectations.
India’s Hilleman Laboratories says it’s aiming to develop an affordable vaccine that will target pregnant women in low- and middle-income countries to prevent Group B Streptococcus, a potentially fatal infection passed to babies during childbirth.
Chi-Med’s surufatinib has come up trumps in a second trial in neuroendocrine tumors, after the monitoring committee recommended an early halt following achievement of its PFS target in the pancreatic setting.